# ARGX catalysts: ARGENX SE PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/argx/catalysts

> ARGENX SE (ARGX) has 58 upcoming catalysts. The next is the empasiprubart topline data readout, Dec 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | ARGENX SE |
| Ticker | ARGX (Nasdaq) |
| SEC CIK | 1697862 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/argx |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 17, 2021 | [Vyvgart (efgartigimod alfa) FDA approval](https://sec-api.dev/pdufa/efgartigimod-alfa) | ARGX |  | completed, approved | "BLA761195 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20211217, review_priority STANDARD; sponsor_name ARGENX BV; product VYVGART (EFGARTIGIMOD ALFA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761195%22)) |
| March 22, 2022 | [VYVGART (efgartigimod) topline data readout](https://sec-api.dev/pdufa/efgartigimod) | ARGX | gMG | completed, met | "On March 22, 2022, we announced positive topline results from the Phase 3 ADAPT-SC clinical trial, a registrational non-inferiority bridging clinical trial of efgartigimod SC for the treatment of gMG. efgartigimod SC achieved the primary endpoint of total IgG reduction from baseline at day 29, demonstrating statistical noninferiority to VYVGART IV formulation in gMG patients." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786225000020/argenx-integratedannualr.htm)) |
| June 20, 2023 | [Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) FDA approval](https://sec-api.dev/pdufa/efgartigimod-alfa-and-hyaluronidase-qvfc) | ARGX |  | completed, approved | "BLA761304 ORIG-1: submission_status AP, submission_status_date 20230620, review_priority PRIORITY; sponsor_name ARGENX BV; product VYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761304%22)) |
| Jul 2023 | [Vyvgart (efgartigimod alfa) topline data readout](https://sec-api.dev/pdufa/efgartigimod-alfa) | ARGX |  | completed, positive | "In July 2023, we announced positive topline results from the ADHERE clinical trial evaluating VYVGART SC (efgartigimod alfa and hyaluronidase-qvfc) in adults with CIDP." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786225000020/argenx-integratedannualr.htm)) |
| June 21, 2024 | [VYVGART (efgartigimod) FDA approval](https://sec-api.dev/pdufa/efgartigimod) | ARGX |  | completed, approved | "For instance, in 2024, we announced the FDA approval of VYVGART HYTRULO for CIDP on June 21, 2024, which positively influenced the stock price between June 15, 2024 and July 1, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786225000020/argenx-integratedannualr.htm)) |
| June 21, 2024 | [Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) label expansion decision](https://sec-api.dev/pdufa/efgartigimod-alfa-and-hyaluronidase-qvfc) | ARGX |  | completed, approved | "BLA761304 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20240621, review_priority PRIORITY; sponsor_name ARGENX BV; product VYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761304%22)) |
| August 8, 2024 | [Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) label expansion decision](https://sec-api.dev/pdufa/efgartigimod-alfa-and-hyaluronidase-qvfc) | ARGX |  | completed, approved | "BLA761304 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20240808, review_priority STANDARD; sponsor_name ARGENX BV; product VYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761304%22)) |
| August 8, 2024 | [Vyvgart (efgartigimod alfa) label expansion decision](https://sec-api.dev/pdufa/efgartigimod-alfa) | ARGX |  | completed, approved | "BLA761195 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20240808, review_priority STANDARD; sponsor_name ARGENX BV; product VYVGART (EFGARTIGIMOD ALFA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761195%22)) |
| 1H 2025 | [Empasiprubart trial start](https://sec-api.dev/pdufa/empasiprubart) | ARGX |  | scheduled | "We also announced CIDP as the 4th indication for empasiprubart during our R&D Day on July 16, 2024 and plan to start a registrational study in CIDP evaluating empasiprubart head-to-head versus intravenous IgG (IVIg) in first half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786225000020/argenx-integratedannualr.htm)) |
| April 10, 2025 | [ARGENX SE PDUFA date](https://sec-api.dev/companies/argx/catalysts) | ARGX |  | scheduled | "We filed for approval of the PFS for gMG and CIDP in the U.S. with a PDUFA Date of April 10, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786225000020/argenx-integratedannualr.htm)) |
| April 10, 2025 | [Vyvgart (efgartigimod alfa) FDA approval](https://sec-api.dev/pdufa/efgartigimod-alfa) | ARGX |  | completed, approved | "Exhibit 99.1 argenx Announces FDA Approval of" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000110465925033857/tm2511923d1_ex99-1.htm)) |
| April 10, 2025 | [VYVGART (efgartigimod) FDA approval](https://sec-api.dev/pdufa/efgartigimod) | ARGX |  | completed, approved | "SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) approved a new option for patients to self-inject VYVGART®" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000110465925033857/tm2511923d1_ex99-1.htm)) |
| April 10, 2025 | [VYVGART (efgartigimod) PDUFA date](https://sec-api.dev/pdufa/efgartigimod) | ARGX |  | completed, approved | "This vision has already started to take shape as we continue to innovate on the patient experience with our pre- filled syringe (VYVGART SC) (with an expected Prescription Drug User Fee Act target action date (PDUFA Date) of April 10, 2025) and the auto-injector approval expected in 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786225000020/argenx-integratedannualr.htm)) |
| April 10, 2025 | [Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) label expansion decision](https://sec-api.dev/pdufa/efgartigimod-alfa-and-hyaluronidase-qvfc) | ARGX |  | completed, approved | "BLA761304 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20250410, review_priority STANDARD; sponsor_name ARGENX BV; product VYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761304%22)) |
| June 30, 2025 | [Efgartigimod iv primary completion](https://sec-api.dev/pdufa/efgartigimod-iv) | ARGX | Generalized Myasthenia Gravis; gMG; Myasthenia Gravis, Generalized | completed | "NCT06298552 (A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-06-30 (ACTUAL); Lead Sponsor argenx; Results First Posted 2026-08-10." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06298552)) |
| 2H 2025 | [Adimanebart topline data readout](https://sec-api.dev/pdufa/adimanebart) | ARGX |  | scheduled | "(8) its plans to develop ARGX-119, including: (a) Phase 1b proof-of-concept study in CMS, with topline results expected in second half of 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786225000028/a02earningspressreleaseq1.htm)) |
| 2H 2025 | [Empasiprubart topline data readout](https://sec-api.dev/pdufa/empasiprubart) | ARGX |  | scheduled | "•Topline results expected for DGF in the second half of 2025 and for DM in first half of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786225000042/a04earningspressreleasehy.htm)) |
| July 2, 2025 | [Efgartigimod iv primary completion](https://sec-api.dev/pdufa/efgartigimod-iv) | ARGX | Lupus Nephritis | completed | "NCT05810948 (A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-02 (ACTUAL); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05810948)) |
| August 25, 2025 | [ARGENX SE topline data readout](https://sec-api.dev/companies/argx/catalysts) | ARGX |  | completed, positive | "Amsterdam, the Netherlands - argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced positive topline data from the pivotal ADAPT SERON study of" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000110465925082118/tm2524211d1_ex99-1.htm)) |
| late 2025 | [ARGENX SE topline data readout](https://sec-api.dev/companies/argx/catalysts) | ARGX |  | scheduled | "•Topline data from Phase 2 VARVARA study (DGF) expected around year-end 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786225000059/a02earningspressreleaseq3.htm)) |
| Q4 2025 | [VYVGART (efgartigimod) topline data readout](https://sec-api.dev/pdufa/efgartigimod) | ARGX |  | scheduled | "(4) ongoing proof-of-concept studies in LN, SSc, and AMR, with topline results expected in fourth quarter of 2025, second half of 2026, and 2027, respectively" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786225000006/a09earningspressreleaseq42.htm)) |
| October 16, 2025 | [ARGX-117 primary completion](https://sec-api.dev/pdufa/argx-117) | ARGX | Delayed Graft Function | completed | "NCT05907096 (ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-10-16 (ACTUAL); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05907096)) |
| October 17, 2025 | [Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) label expansion decision](https://sec-api.dev/pdufa/efgartigimod-alfa-and-hyaluronidase-qvfc) | ARGX |  | completed, approved | "BLA761304 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20251017, review_priority STANDARD; sponsor_name ARGENX BV; product VYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761304%22)) |
| October 17, 2025 | [Vyvgart (efgartigimod alfa) label expansion decision](https://sec-api.dev/pdufa/efgartigimod-alfa) | ARGX |  | completed, approved | "BLA761195 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20251017, review_priority STANDARD; sponsor_name ARGENX BV; product VYVGART (EFGARTIGIMOD ALFA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761195%22)) |
| December 15, 2025 | [Efgartigimod ph20 sc primary completion](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) | ARGX | Thyroid Eye Disease | withdrawn | "NCT06307613 (A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-12-15 (ACTUAL); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06307613)) |
| December 15, 2025 | [Efgartigimod ph20 sc primary completion](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) | ARGX | Thyroid Eye Disease | withdrawn | "NCT06307626 (A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-12-15 (ACTUAL); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06307626)) |
| 1H 2026 | [Empasiprubart topline data readout](https://sec-api.dev/pdufa/empasiprubart) | ARGX |  | scheduled | "Topline results expected 1H 2026. argenx Annual Report 2024 2024 In Brief 16 empasiprubart ARGX-119" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786225000020/argenx-integratedannualr.htm)) |
| Q1 2026 | [ARGENX SE topline data readout](https://sec-api.dev/companies/argx/catalysts) | ARGX |  | scheduled | "Topline results expected for ocular MG (ADAPT OCULUS) in first quarter of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000110465926002867/tm262664d1_ex99-1.htm)) |
| 1H 2026 | [Adimanebart topline data readout](https://sec-api.dev/pdufa/adimanebart) | ARGX |  | scheduled | "(b) Phase 2a proof-of-concept study in ALS, with topline results expected in first half of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786225000028/a02earningspressreleaseq1.htm)) |
| Jan 2026 | [VYVGART (efgartigimod) NDA/BLA acceptance](https://sec-api.dev/pdufa/efgartigimod) | ARGX | with Seronegative gMG | completed | "In January 2026, the FDA has accepted for priority review a supplemental BLA for VYVGART for the treatment of adults with Seronegative gMG." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786226000030/argenx2025integratedannu.htm)) |
| 1H 2026 | [VYVGART (efgartigimod) topline data readout](https://sec-api.dev/pdufa/efgartigimod) | ARGX |  | scheduled | "the advancement of anticipated clinical development, data readouts and regulatory milestones and plans, including: (1) the PFS decision on approval expected in Canada by end of 2025, (2) the filing of the sBLA for VYVGART in three AChR-Ab seronegative gMG subtypes by year-end 2025, (3) its pursuit of label expansion through ongoing registrational studies, with topline results expected in first half of 2026 for ocular MG and second half of 2026 for primary ITP" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786225000059/a02earningspressreleaseq3.htm)) |
| 1H 2026 | [ARGX-213 topline data readout](https://sec-api.dev/pdufa/argx-213) | ARGX |  | scheduled | "Phase 2a proof-of-concept study in ALS, with topline results expected in first half of 2026; and (c) SMA proof-of- concept study; and (8) its plans to advance four new pipeline molecules and generate sustainable value through continue investment in its IIP, through (a) ongoing studies for ARGX-213 and ARGX-121, with results expected in first half of 2026, (b) ARGX-109, with Phase 1 results expected in second half of 2025, and (c) a fourth pipeline candidate, a first-in-class sweeping antibody for which the target has not yet been disclosed; and its goal of translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786225000042/argx-20250630_d2.htm)) |
| 1H 2026 | [ARGENX SE topline data readout](https://sec-api.dev/companies/argx/catalysts) | ARGX |  | scheduled | "•Phase 2a proof-of-concept study ongoing in ALS; topline results expected in first half of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786225000059/a02earningspressreleaseq3.htm)) |
| January 12, 2026 | [Efgartigimod ph20 sc primary completion](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) | ARGX | Myasthenia Gravis, Ocular | completed | "NCT06558279 (A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-01-12 (ACTUAL); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06558279)) |
| February 26, 2026 | [Vyvgart (efgartigimod alfa) topline data readout](https://sec-api.dev/pdufa/efgartigimod-alfa) | ARGX | ocular myasthenia gravis | completed, positive | "SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART® (efgartigimod alfa and hyaluronidase-qvfc) in adults with ocular myasthenia gravis (oMG)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000110465926020017/tm267379d1_ex99-1.htm)) |
| March 11, 2026 | [VYVGART (efgartigimod) primary completion](https://sec-api.dev/pdufa/efgartigimod) | ARGX | Primary Immune Thrombocytopenia | completed | "NCT04225156 (A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-03-11 (ACTUAL); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04225156)) |
| May 8, 2026 | [Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) label expansion decision](https://sec-api.dev/pdufa/efgartigimod-alfa-and-hyaluronidase-qvfc) | ARGX |  | completed, approved | "BLA761304 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20260508, review_priority PRIORITY; sponsor_name ARGENX BV; product VYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761304%22)) |
| May 8, 2026 | [Vyvgart (efgartigimod alfa) label expansion decision](https://sec-api.dev/pdufa/efgartigimod-alfa) | ARGX |  | completed, approved | "BLA761195 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20260508, review_priority PRIORITY; sponsor_name ARGENX BV; product VYVGART (EFGARTIGIMOD ALFA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761195%22)) |
| May 10, 2026 | [VYVGART (efgartigimod) PDUFA date](https://sec-api.dev/pdufa/efgartigimod) | ARGX |  | scheduled | "These data support our supplemental regulatory submission to expand VYVGART into the seronegative population, which was accpeted for priority review with an expected PDUFA target action date of May 10, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786226000030/argenx2025integratedannu.htm)) |
| Q3 2026 | [VYVGART (efgartigimod) topline data readout](https://sec-api.dev/pdufa/efgartigimod) | ARGX |  | scheduled | "Topline results expected in the third quarter of 2026 from ALKIVIA clinical trial evaluating three myositis subsetsIMNM,ASyS and DM with efgartigimod" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786226000030/argenx2025integratedannu.htm)) |
| Q3 2026 | [ARGENX SE topline data readout](https://sec-api.dev/companies/argx/catalysts) | ARGX |  | scheduled | "•Topline results from registrational ALKIVIA study (myositis) expected in third quarter of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786226000033/a04earningspressreleasehy.htm)) |
| Q3 2026 | [ARGENX SE topline data readout](https://sec-api.dev/companies/argx/catalysts) | ARGX |  | scheduled | "•Topline results from ALKIVIA study (myositis) expected in third quarter of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000162828026031739/a02earningspressreleaseq1.htm)) |
| Q3 2026 | [VYVGART (efgartigimod) NDA/BLA submission](https://sec-api.dev/pdufa/efgartigimod) | ARGX |  | scheduled | "argenx's vision of delivering a targeted, transformative treatment option to as many MG patients as possible; its expectation that it will submit a Supplemental Biologics License Application (sBLA) for VYVGART for oMG to the U.S. FDA by end of third quarter 2026;" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000110465926020017/tm267379d1_ex99-1.htm)) |
| July 2, 2026 | [Efg ph20 sc primary completion](https://sec-api.dev/pdufa/efg-ph20-sc) | ARGX | Active Idiopathic Inflammatory Myopathy; Myositis; Dermatomyositis | completed | "NCT05523167 (A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2026-07-02 (ACTUAL); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05523167)) |
| August 10, 2026 | [Efgartigimod iv topline data readout](https://sec-api.dev/pdufa/efgartigimod-iv) | ARGX | Generalized Myasthenia Gravis; gMG; Myasthenia Gravis, Generalized | completed | "NCT06298552 (A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-06-30 (ACTUAL); Lead Sponsor argenx; Results First Posted 2026-08-10." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06298552?tab=results)) |
| August 12, 2026 | [ARGX-119 primary completion](https://sec-api.dev/pdufa/argx-119) | ARGX | Amyotrophic Lateral Sclerosis | withdrawn | "NCT06441682 (A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-08-12 (ACTUAL); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06441682)) |
| August 17, 2026 | [Vyvgart (efgartigimod alfa) topline data readout](https://sec-api.dev/pdufa/efgartigimod-alfa) | ARGX | autoimmune myositis | completed, positive | "Amsterdam, the Netherlands - argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced positive topline results from the ALKIVIA Phase 3 study evaluating VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000110465926097589/tm2623372d1_ex99-1.htm)) |
| September 2026 | [Empasiprubart primary completion](https://sec-api.dev/pdufa/empasiprubart) | ARGX | Multifocal Motor Neuropathy (MMN); MMN | delayed | "NCT06742190 (A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06742190)) |
| Q4 2026 | [VYVGART (efgartigimod) topline data readout](https://sec-api.dev/pdufa/efgartigimod) | ARGX |  | scheduled | "Topline results expected in the fourth quarter of 2026 for primary ITP (ADVANCE-NEXT) with efgartigimod" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786226000030/argenx2025integratedannu.htm)) |
| Q4 2026 | [ARGENX SE topline data readout](https://sec-api.dev/companies/argx/catalysts) | ARGX |  | scheduled | "•Topline results from EMPASSION study (MMN) expected in fourth quarter of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000162828026031739/a02earningspressreleaseq1.htm)) |
| October 8, 2026 | [FB102 topline data readout](https://sec-api.dev/pdufa/fb102) | ARGX | celiac disease | completed, positive | "Amsterdam, the Netherlands - argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced positive topline results from the Phase 2 study evaluating FB102, a first-in-class CD122 inhibitor, in adults with celiac disease." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000110465926114491/tm2627263d1_ex99-1.htm)) |
| November 2026 | [Empasiprubart iv primary completion](https://sec-api.dev/pdufa/empasiprubart-iv) | ARGX | Dermatomyositis; Myositis | scheduled | "NCT06284954 (A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06284954)) |
| Nov 2026 to Feb 2027 | [Empasiprubart iv topline data readout](https://sec-api.dev/pdufa/empasiprubart-iv) | ARGX | Dermatomyositis; Myositis | scheduled | "NCT06284954 (A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06284954)) |
| Dec 2026 | [Empasiprubart topline data readout](https://sec-api.dev/pdufa/empasiprubart) | ARGX | Multifocal Motor Neuropathy (MMN); MMN | scheduled | "•Topline results from the Phase 3 EMPASSION study (MMN) expected in December 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786226000034/a02earningspressreleaseq3.htm)) |
| 1H 2027 | [ARGENX SE topline data readout](https://sec-api.dev/companies/argx/catalysts) | ARGX |  | scheduled | "•Topline results from ADVANCE-NEXT study (primary ITP) expected in first half of 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000162828026031739/a02earningspressreleaseq1.htm)) |
| 1H 2027 | [ARGENX SE topline data readout](https://sec-api.dev/companies/argx/catalysts) | ARGX |  | scheduled | "•Topline results from registrational ADVANCE-NEXT study (primary ITP) expected in first half of 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786226000033/a04earningspressreleasehy.htm)) |
| 1H 2027 | [ARGENX SE topline data readout](https://sec-api.dev/companies/argx/catalysts) | ARGX |  | scheduled | "•Topline results from Phase 3 ADVANCE-NEXT study in primary ITP expected in first half of 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786226000034/a02earningspressreleaseq3.htm)) |
| Feb 2027 | [VYVGART (efgartigimod) PDUFA date](https://sec-api.dev/pdufa/efgartigimod) | ARGX |  | scheduled | "•sBLA for VYVGART and VYVGART Hytrulo in pediatric gMG accepted for priority review by the FDA, with a PDUFA target action date in February 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786226000034/a02earningspressreleaseq3.htm)) |
| March 2027 | [Efgartigimod iv primary completion](https://sec-api.dev/pdufa/efgartigimod-iv) | ARGX | Generalized Myasthenia Gravis | scheduled | "NCT04833894 (Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04833894)) |
| Mar to Jun 2027 | [Efgartigimod iv topline data readout](https://sec-api.dev/pdufa/efgartigimod-iv) | ARGX | Generalized Myasthenia Gravis | scheduled | "NCT04833894 (Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04833894)) |
| March 2027 | [Efgartigimod ph20 sc primary completion](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) | ARGX | Systemic Sclerosis (SSc) | scheduled | "NCT06655155 (A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06655155)) |
| Mar to Jun 2027 | [Efgartigimod ph20 sc topline data readout](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) | ARGX | Systemic Sclerosis (SSc) | scheduled | "NCT06655155 (A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06655155)) |
| Apr to Jul 2027 | [Efgartigimod ph20 sc topline data readout](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) | ARGX | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | scheduled | "NCT04280718 (A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-30 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04280718)) |
| April 2027 | [Efgartigimod ph20 sc primary completion](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) | ARGX | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | scheduled | "NCT04280718 (A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-30 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04280718)) |
| 2H 2027 | [VYVGART (efgartigimod) topline data readout](https://sec-api.dev/pdufa/efgartigimod) | ARGX |  | scheduled | "Topline results from UNITY clinical trial (SjD) expected in second half of 2027 with efgartigimod" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786226000030/argenx2025integratedannu.htm)) |
| 2H 2027 | [ARGENX SE topline data readout](https://sec-api.dev/companies/argx/catalysts) | ARGX |  | scheduled | "•Topline results from Phase 3 EMVIGORATE and EMNERGIZE studies in CIDP anticipated in the second half of 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786226000034/a02earningspressreleaseq3.htm)) |
| 2H 2027 | [ARGENX SE topline data readout](https://sec-api.dev/companies/argx/catalysts) | ARGX |  | scheduled | "•Topline results from UNITY study (Sjogren's disease) expected in second half of 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000162828026031739/a02earningspressreleaseq1.htm)) |
| 2H 2027 | [Adimanebart topline data readout](https://sec-api.dev/pdufa/adimanebart) | ARGX |  | scheduled | "Topline results from both EMVIGORATE and EMNERGIZE are expected in the second half of 2027. 1.3.5 adimanebart (ARGX-119) Development adimanebart is a humanized agonist monoclonal antibody that specifically targets and activates MuSK to promote maturation and stabilization of the NMJ, with planned development across severe neuromuscular diseases including CMS, ALS, and SMA." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786226000030/argenx2025integratedannu.htm)) |
| 2H 2027 | [ARGENX SE topline data readout](https://sec-api.dev/companies/argx/catalysts) | ARGX |  | scheduled | "•Topline results from registrational UNITY study (Sjogren's disease) expected in second half of 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786226000033/a04earningspressreleasehy.htm)) |
| July 2027 | [Efgartigimod ph20 sc primary completion](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) | ARGX | Primary Sjogrens Disease | scheduled | "NCT06684847 (A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06684847)) |
| Jul to Oct 2027 | [Efgartigimod ph20 sc topline data readout](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) | ARGX | Primary Sjogrens Disease | scheduled | "NCT06684847 (A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06684847)) |
| September 2027 | [Efgartigimod ph20 sc primary completion](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) | ARGX | Generalized Myasthenia Gravis | scheduled | "NCT06392386 (A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06392386)) |
| Sep to Dec 2027 | [Efgartigimod ph20 sc topline data readout](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) | ARGX | Generalized Myasthenia Gravis | scheduled | "NCT06392386 (A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06392386)) |
| September 2027 | [Empasiprubart primary completion](https://sec-api.dev/pdufa/empasiprubart) | ARGX |  | scheduled | "NCT06920004 (A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06920004)) |
| Sep to Dec 2027 | [Empasiprubart topline data readout](https://sec-api.dev/pdufa/empasiprubart) | ARGX |  | scheduled | "NCT06920004 (A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06920004)) |
| October 2027 | [Efgartigimod ph20 sc primary completion](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) | ARGX | Primary Immune Thrombocytopenia | scheduled | "NCT04812925 (A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04812925)) |
| Oct 2027 to Jan 2028 | [Efgartigimod ph20 sc topline data readout](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) | ARGX | Primary Immune Thrombocytopenia | scheduled | "NCT04812925 (A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04812925)) |
| Oct 2027 to Jan 2028 | [Empasiprubart iv topline data readout](https://sec-api.dev/pdufa/empasiprubart-iv) | ARGX |  | scheduled | "NCT07091630 (A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-07 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07091630)) |
| October 2027 | [Empasiprubart iv primary completion](https://sec-api.dev/pdufa/empasiprubart-iv) | ARGX |  | scheduled | "NCT07673627 (ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07673627)) |
| Oct 2027 to Jan 2028 | [Empasiprubart iv topline data readout](https://sec-api.dev/pdufa/empasiprubart-iv) | ARGX |  | scheduled | "NCT07673627 (ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07673627)) |
| October 2027 | [Empasiprubart iv primary completion](https://sec-api.dev/pdufa/empasiprubart-iv) | ARGX |  | scheduled | "NCT07091630 (A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-07 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07091630)) |
| November 2027 | [Efgartigimod ph20 sc - prefilled syringe primary completion](https://sec-api.dev/pdufa/efgartigimod-ph20-sc-prefilled-syringe) | ARGX | Antibody-mediated Rejection | scheduled | "NCT06503731 (A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06503731)) |
| Nov 2027 to Feb 2028 | [Efgartigimod ph20 sc - prefilled syringe topline data readout](https://sec-api.dev/pdufa/efgartigimod-ph20-sc-prefilled-syringe) | ARGX | Antibody-mediated Rejection | scheduled | "NCT06503731 (A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06503731)) |
| January 2028 | [Empasiprubart iv primary completion](https://sec-api.dev/pdufa/empasiprubart-iv) | ARGX | Guillain-Barré Syndrome (GBS) | scheduled | "NCT07821762 (A Study of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barré Syndrome): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07821762)) |
| Jan to Apr 2028 | [Empasiprubart iv topline data readout](https://sec-api.dev/pdufa/empasiprubart-iv) | ARGX | Guillain-Barré Syndrome (GBS) | scheduled | "NCT07821762 (A Study of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barré Syndrome): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07821762)) |
| Mar to Jun 2028 | [Efgartigimod iv topline data readout](https://sec-api.dev/pdufa/efgartigimod-iv) | ARGX | AChR-Ab Seropositive Generalized Myasthenia Gravis; Myasthenia Gravis; MG | scheduled | "NCT07284420 (ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-07 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07284420)) |
| March 2028 | [Efgartigimod iv primary completion](https://sec-api.dev/pdufa/efgartigimod-iv) | ARGX | AChR-Ab Seropositive Generalized Myasthenia Gravis; Myasthenia Gravis; MG | scheduled | "NCT07284420 (ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-07 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07284420)) |
| June 2028 | [Efgartigimod iv primary completion](https://sec-api.dev/pdufa/efgartigimod-iv) | ARGX | Primary Immune Thrombocytopenia (ITP) | scheduled | "NCT06544499 (A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06544499)) |
| Jun to Sep 2028 | [Efgartigimod iv topline data readout](https://sec-api.dev/pdufa/efgartigimod-iv) | ARGX | Primary Immune Thrombocytopenia (ITP) | scheduled | "NCT06544499 (A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06544499)) |
| June 2028 | [Efgartigimod ph20 sc primary completion](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) | ARGX | Graves' Disease; Graves Disease | scheduled | "NCT07570316 (A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07570316)) |
| Jun to Sep 2028 | [Efgartigimod ph20 sc topline data readout](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) | ARGX | Graves' Disease; Graves Disease | scheduled | "NCT07570316 (A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07570316)) |
| June 2028 | [Efgartigimod ph20 sc primary completion](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) | ARGX | Graves Disease | scheduled | "NCT07596849 (A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07596849)) |
| Jun to Sep 2028 | [Efgartigimod ph20 sc topline data readout](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) | ARGX | Graves Disease | scheduled | "NCT07596849 (A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07596849)) |
| Jul to Oct 2028 | [Efgartigimod ph20 sc topline data readout](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) | ARGX | Sjogrens Disease; Primary Sjögren's Syndrome Painful Sensory Neuropathies | scheduled | "NCT07760818 (A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-07-28 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07760818)) |
| July 2028 | [Efgartigimod ph20 sc primary completion](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) | ARGX | Sjogrens Disease; Primary Sjögren's Syndrome Painful Sensory Neuropathies | scheduled | "NCT07760818 (A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-07-28 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07760818)) |
| September 2028 | [Efgartigimod ph20 sc primary completion](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) | ARGX | Myositis; Active Idiopathic Inflammatory Myopathy; Dermatomyositis | scheduled | "NCT05979441 (A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-09 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05979441)) |
| Sep to Dec 2028 | [Efgartigimod ph20 sc topline data readout](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) | ARGX | Myositis; Active Idiopathic Inflammatory Myopathy; Dermatomyositis | scheduled | "NCT05979441 (A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-09 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05979441)) |
| October 2028 | [Efgartigimod iv primary completion](https://sec-api.dev/pdufa/efgartigimod-iv) | ARGX | Immune Thrombocytopenia (ITP); ITP - Immune Thrombocytopenia; ITP | scheduled | "NCT07194850 (A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-10 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07194850)) |
| Oct 2028 to Jan 2029 | [Efgartigimod iv topline data readout](https://sec-api.dev/pdufa/efgartigimod-iv) | ARGX | Immune Thrombocytopenia (ITP); ITP - Immune Thrombocytopenia; ITP | scheduled | "NCT07194850 (A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-10 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07194850)) |
| May to Aug 2029 | [Argx-119 iv topline data readout](https://sec-api.dev/pdufa/argx-119-iv) | ARGX | Spinal Muscular Atrophy (SMA) | scheduled | "NCT07287982 (A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05-28 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07287982)) |
| May 2029 | [Argx-119 iv primary completion](https://sec-api.dev/pdufa/argx-119-iv) | ARGX | Spinal Muscular Atrophy (SMA) | scheduled | "NCT07287982 (A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05-28 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07287982)) |
| September 2029 | [Efgartigimod iv or efgartigimod ph20 sc primary completion](https://sec-api.dev/pdufa/efgartigimod-iv-or-efgartigimod-ph20-sc) | ARGX | Generalized Myasthenia Gravis; gMG | scheduled | "NCT05374590 (Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2, PHASE3; Primary Completion 2029-09 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05374590)) |
| Sep to Dec 2029 | [Efgartigimod iv or efgartigimod ph20 sc topline data readout](https://sec-api.dev/pdufa/efgartigimod-iv-or-efgartigimod-ph20-sc) | ARGX | Generalized Myasthenia Gravis; gMG | scheduled | "NCT05374590 (Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2, PHASE3; Primary Completion 2029-09 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05374590)) |
| Sep to Dec 2029 | [ARGX-117 topline data readout](https://sec-api.dev/pdufa/argx-117) | ARGX | Multifocal Motor Neuropathy (MMN) | scheduled | "NCT05405361 (A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-09-30 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05405361)) |
| September 2029 | [ARGX-117 primary completion](https://sec-api.dev/pdufa/argx-117) | ARGX | Multifocal Motor Neuropathy (MMN) | scheduled | "NCT05405361 (A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-09-30 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05405361)) |
| Oct 2029 to Jan 2030 | [ARGX-121 topline data readout](https://sec-api.dev/pdufa/argx-121) | ARGX | Immunoglobulin A Nephropathy (IgAN) | scheduled | "NCT07773727 (A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-10-29 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07773727)) |
| October 2029 | [ARGX-121 primary completion](https://sec-api.dev/pdufa/argx-121) | ARGX | Immunoglobulin A Nephropathy (IgAN) | scheduled | "NCT07773727 (A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-10-29 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07773727)) |
| July 2030 | [Efgartigimod ph20 (argx-113) sc primary completion](https://sec-api.dev/pdufa/efgartigimod-ph20-argx-113-sc) | ARGX | Autoimmune Encephalitis (AE) | scheduled | "NCT07583641 (A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2030-07 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07583641)) |
| Jul to Oct 2030 | [Efgartigimod ph20 (argx-113) sc topline data readout](https://sec-api.dev/pdufa/efgartigimod-ph20-argx-113-sc) | ARGX | Autoimmune Encephalitis (AE) | scheduled | "NCT07583641 (A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2030-07 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07583641)) |
| October 2030 | [Adimanebart iv primary completion](https://sec-api.dev/pdufa/adimanebart-iv) | ARGX | Congenital Myasthenic Syndrome; CMS | scheduled | "NCT07746089 (A Study to Assess Efficacy and Safety of Adimanebart in Adult and Pediatric Participants With DOK7-,MUSK-, AGRN-, or LRP4- Congenital Myasthenic Syndromes (CMS)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-10 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07746089)) |
| Oct 2030 to Jan 2031 | [Adimanebart iv topline data readout](https://sec-api.dev/pdufa/adimanebart-iv) | ARGX | Congenital Myasthenic Syndrome; CMS | scheduled | "NCT07746089 (A Study to Assess Efficacy and Safety of Adimanebart in Adult and Pediatric Participants With DOK7-,MUSK-, AGRN-, or LRP4- Congenital Myasthenic Syndromes (CMS)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-10 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07746089)) |

## Drugs

- [Adimanebart](https://sec-api.dev/pdufa/adimanebart): 
- [Adimanebart iv](https://sec-api.dev/pdufa/adimanebart-iv): Congenital Myasthenic Syndrome
- [ARGX-117](https://sec-api.dev/pdufa/argx-117): Multifocal Motor Neuropathy (MMN), Delayed Graft Function
- [ARGX-119](https://sec-api.dev/pdufa/argx-119): Amyotrophic Lateral Sclerosis
- [Argx-119 iv](https://sec-api.dev/pdufa/argx-119-iv): Spinal Muscular Atrophy (SMA)
- [ARGX-121](https://sec-api.dev/pdufa/argx-121): Immunoglobulin A Nephropathy (IgAN)
- [ARGX-213](https://sec-api.dev/pdufa/argx-213): 
- [Efg ph20 sc](https://sec-api.dev/pdufa/efg-ph20-sc): Active Idiopathic Inflammatory Myopathy
- [VYVGART (efgartigimod)](https://sec-api.dev/pdufa/efgartigimod): gmg, achr-antibody-positive mg, autoimmune myositis, myasthenia gravis, with seronegative gmg, Primary Immune Thrombocytopenia
- [Vyvgart (efgartigimod alfa)](https://sec-api.dev/pdufa/efgartigimod-alfa): autoimmune myositis, ocular myasthenia gravis
- [Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)](https://sec-api.dev/pdufa/efgartigimod-alfa-and-hyaluronidase-qvfc): 
- [Efgartigimod iv](https://sec-api.dev/pdufa/efgartigimod-iv): AChR-Ab Seropositive Generalized Myasthenia Gravis, Lupus Nephritis, Primary Immune Thrombocytopenia (ITP), Generalized Myasthenia Gravis, Immune Thrombocytopenia (ITP)
- [Efgartigimod iv or efgartigimod ph20 sc](https://sec-api.dev/pdufa/efgartigimod-iv-or-efgartigimod-ph20-sc): Generalized Myasthenia Gravis
- [Efgartigimod ph20 (argx-113) sc](https://sec-api.dev/pdufa/efgartigimod-ph20-argx-113-sc): Autoimmune Encephalitis (AE)
- [Efgartigimod ph20 sc](https://sec-api.dev/pdufa/efgartigimod-ph20-sc): Primary Immune Thrombocytopenia, Sjogrens Disease, Myasthenia Gravis, Ocular, Myositis, Generalized Myasthenia Gravis, Thyroid Eye Disease, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Sjogrens Disease, Graves' Disease, Graves Disease, Systemic Sclerosis (SSc)
- [Efgartigimod ph20 sc - prefilled syringe](https://sec-api.dev/pdufa/efgartigimod-ph20-sc-prefilled-syringe): Antibody-mediated Rejection
- [Empasiprubart](https://sec-api.dev/pdufa/empasiprubart): Multifocal Motor Neuropathy (MMN), Chronic Inflammatory Demyelinating Polyneuropathy
- [Empasiprubart iv](https://sec-api.dev/pdufa/empasiprubart-iv): Dermatomyositis, AChR-Ab Seropositive Generalized Myasthenia Gravis, Guillain-Barré Syndrome (GBS), Chronic Inflammatory Demyelinating Polyneuropathy
- [FB102](https://sec-api.dev/pdufa/fb102): celiac disease

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/argx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ARGX catalysts: ARGENX SE PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/argx/catalysts

```bibtex
@misc{secapidev_companies_argx_catalysts_20261116,
  title        = {ARGX catalysts: ARGENX SE PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/argx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_argx_catalysts_20261116","title":"ARGX catalysts: ARGENX SE PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/argx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
